Moleculin (MBRX) director granted 150,000 options at $0.49

Moleculin Biotech (MBRX) reported a director’s grant of 150,000 stock options (Transaction Code A) at an exercise price of $0.49 on November 12, 2025.

Accepted by SEC EDGAR 11/14/2025 - 04:06 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Moleculin Biotech (MBRX) reported a director’s grant of 150,000 stock options (Transaction Code A) at an exercise price of $0.49 on November 12, 2025.

The options vest on November 12, 2026, subject to continued Board service, and expire on November 12, 2035. Following this grant, the reporting person beneficially owned 165,336 derivative securities, held directly. The filing notes the options were issued in connection with Board service.

Insider Trade Summary

Grant/Award: 150,000 shares

Grant/Award 1 txn

Insider CANNON MICHAEL D

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Options (right to buy)	150,000	$0.00	$0.00

Holdings After Transaction: Stock Options (right to buy) — 165,336 contracts (Direct)

Holdings Before and After: Stock Options (right to buy), 15,336 to 165,336 contracts (Direct)

Footnotes (2)

1. F1. The options set forth in this table vest on November 12, 2026, subject to the grantee's continued service on the Company's Board of Directors on each vesting date.
2. F2. The options were issued in connection with the reporting person's Board of Director service to the Company.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Moleculin Biotech (MBRX) report in this Form 4?

A director received a grant of 150,000 stock options at an exercise price of $0.49 on November 12, 2025.

What is the exercise price and timing for the MBRX director options?

The options have an exercise price of $0.49, vest on November 12, 2026, and expire on November 12, 2035.

How many derivative securities are owned after the reported transaction?

The reporting person beneficially owned 165,336 derivative securities following the transaction.

What role does the reporting person have at Moleculin Biotech (MBRX)?

The reporting person is a Director.

Why were the options granted to the MBRX director?

They were issued in connection with the reporting person’s Board of Director service to the company.

What is the transaction code used in this Form 4?

The transaction code is A, indicating an award/grant of derivative securities.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

CANNON MICHAEL D

(Last) (First) (Middle)

C/O MOLECULIN BIOTECH, INC.

5300 MEMORIAL DR., SUITE 950

(Street)

HOUSTON TX 77007

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Moleculin Biotech, Inc. [ MBRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
11/12/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options (right to buy)	$0.49	11/12/2025		A		150,000		11/12/2026(1)	11/12/2035	Common Stock	150,000	(2)	165,336	D

Explanation of Responses:

1. The options set forth in this table vest on November 12, 2026, subject to the grantee's continued service on the Company's Board of Directors on each vesting date.

2. The options were issued in connection with the reporting person's Board of Director service to the Company.

	/s/ Jonathan Foster by Power of Attorney	11/14/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.